Transcend Capital Advisors, LLC Biogen Inc. Transaction History

Transcend Capital Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$253.3 - $285.89 $8,865 - $10,006	-35 Reduced 2.38%	1,435 $368,000
Q2 2023 Jul 13, 2023	SELL	$275.25 - $318.06 $32,479 - $37,531	-118 Reduced 7.43%	1,470 $418,000
Q1 2023 Apr 12, 2023	SELL	$256.56 - $292.34 $425,119 - $484,407	-1,657 Reduced 51.06%	1,588 $441,000
Q4 2022 Jan 20, 2023	SELL	$252.44 - $306.72 $151,464 - $184,032	-600 Reduced 15.6%	3,245 $0
Q3 2022 Oct 17, 2022	BUY	$194.69 - $268.46 $2,141 - $2,953	11 Added 0.29%	3,845 $1.03 Million
Q2 2022 Jul 12, 2022	BUY	$187.54 - $223.02 $339,259 - $403,443	1,809 Added 89.33%	3,834 $782,000
Q1 2022 Apr 20, 2022	BUY	$193.77 - $244.14 $116,262 - $146,484	600 Added 42.11%	2,025 $426,000
Q4 2021 Jan 20, 2022	BUY	$223.92 - $287.77 $8,508 - $10,935	38 Added 2.74%	1,425 $342,000
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $359,233 - $575,202	1,387 New	1,387 $480,000
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $182,156 - $274,190	-771 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $204,137 - $235,702	771 New	771 $219,000

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Transcend Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Transcend Capital Advisors, LLC with notifications on news.